High-Grade Glioma - Pipeline Review, H2 2017

  • ID: 4446912
  • Drug Pipelines
  • 333 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc
  • Boehringer Ingelheim GmbH
  • CBT Pharmaceuticals Inc
  • Ipsen SA
  • Ono Pharmaceutical Co Ltd
  • MORE
High-Grade Glioma - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H2 2017, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 15, 13 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc
  • Boehringer Ingelheim GmbH
  • CBT Pharmaceuticals Inc
  • Ipsen SA
  • Ono Pharmaceutical Co Ltd
  • MORE
Introduction

High-Grade Glioma - Overview

High-Grade Glioma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

High-Grade Glioma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

High-Grade Glioma - Companies Involved in Therapeutics Development

AbbVie Inc

Advenchen Laboratories LLC

AngioChem Inc

Arog Pharmaceuticals Inc

Astellas Pharma Inc

Athenex Inc

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cavion LLC

CBT Pharmaceuticals Inc

Celgene Corp

Concordia International Corp

DelMar Pharmaceuticals Inc

Eisai Co Ltd

Ipsen SA

Karyopharm Therapeutics Inc

Millennium Pharmaceuticals Inc

Nektar Therapeutics

Northwest Biotherapeutics Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Sanofi

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Targepeutics Inc

Tocagen Inc

ZIOPHARM Oncology Inc

High-Grade Glioma - Drug Profiles

AdRTSIL-12 - Drug Profile

afatinib dimaleate - Drug Profile

alisertib - Drug Profile

apatinib mesylate - Drug Profile

bendamustine hydrochloride - Drug Profile

BMX-001 - Drug Profile

cabazitaxel - Drug Profile

CBT-101 - Drug Profile

Cellular Immunotherapy for High-Grade Glioma - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

crenolanib besylate - Drug Profile

dabrafenib mesylate - Drug Profile

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile

DCVax-L - Drug Profile

depatuxizumab mafodotin - Drug Profile

dianhydrogalactitol - Drug Profile

elatipepimut-S + adegrapepimut-S - Drug Profile

etirinotecan pegol - Drug Profile

flucytosine + TBio-01 - Drug Profile

flucytosine ER + vocimagene amiretrorepvec - Drug Profile

GB-13 - Drug Profile

HSV-1716 - Drug Profile

ipilimumab + nivolumab - Drug Profile

irinotecan hydrochloride - Drug Profile

irinotecan hydrochloride + TBio-02 - Drug Profile

KX-02 - Drug Profile

lenvatinib mesylate - Drug Profile

mibefradil dihydrochloride - Drug Profile

nivolumab - Drug Profile

ONC-206 - Drug Profile

Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile

paclitaxel trevatide - Drug Profile

pomalidomide - Drug Profile

porfimer sodium - Drug Profile

RRX-001 - Drug Profile

selinexor - Drug Profile

sorafenib tosylate - Drug Profile

z-90099 - Drug Profile

High-Grade Glioma - Dormant Projects

High-Grade Glioma - Discontinued Products

High-Grade Glioma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for High-Grade Glioma, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Target, H2 2017 (Contd..1), H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

High-Grade Glioma - Pipeline by AbbVie Inc, H2

High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H2

High-Grade Glioma - Pipeline by AngioChem Inc, H2

High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H2

High-Grade Glioma - Pipeline by Astellas Pharma Inc, H2

High-Grade Glioma - Pipeline by Athenex Inc, H2

High-Grade Glioma - Pipeline by Bayer AG, H2

High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H2

High-Grade Glioma - Pipeline by Bristol-Myers Squibb Co, H2

High-Grade Glioma - Pipeline by Cavion LLC, H2

High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H2

High-Grade Glioma - Pipeline by Celgene Corp, H2

High-Grade Glioma - Pipeline by Concordia International Corp, H2

High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H2

High-Grade Glioma - Pipeline by Eisai Co Ltd, H2

High-Grade Glioma - Pipeline by Ipsen SA, H2

High-Grade Glioma - Pipeline by Karyopharm Therapeutics Inc, H2

High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H2

High-Grade Glioma - Pipeline by Nektar Therapeutics, H2

High-Grade Glioma - Pipeline by Northwest Biotherapeutics Inc, H2

High-Grade Glioma - Pipeline by Novartis AG, H2

High-Grade Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H2

High-Grade Glioma - Pipeline by Sanofi, H2

High-Grade Glioma - Pipeline by Sorrento Therapeutics Inc, H2

High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2

High-Grade Glioma - Pipeline by Targepeutics Inc, H2

High-Grade Glioma - Pipeline by Tocagen Inc, H2

High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H2

High-Grade Glioma - Dormant Projects, H2

High-Grade Glioma - Discontinued Products, H2

List of Figures

Number of Products under Development for High-Grade Glioma, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Top 10 Routes of Administration, H2

Number of Products by Stage and Top 10 Routes of Administration, H2

Number of Products by Top 10 Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Advenchen Laboratories LLC
  • AngioChem Inc
  • Arog Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Athenex Inc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cavion LLC
  • CBT Pharmaceuticals Inc
  • Celgene Corp
  • Concordia International Corp
  • DelMar Pharmaceuticals Inc
  • Eisai Co Ltd
  • Ipsen SA
  • Karyopharm Therapeutics Inc
  • Millennium Pharmaceuticals Inc
  • Nektar Therapeutics
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Sanofi
  • Sorrento Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Targepeutics Inc
  • Tocagen Inc
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll